These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10093013)

  • 21. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
    Ridker PM; Rifai N; Pfeffer MA; Sacks FM; Moye LA; Goldman S; Flaker GC; Braunwald E
    Circulation; 1998 Sep; 98(9):839-44. PubMed ID: 9738637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of lipid metabolism in the prevention of coronary heart disease].
    Mathes P; Thiery J
    Z Kardiol; 2005; 94 Suppl 3():III/43-55. PubMed ID: 16258792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-density lipoprotein size, pravastatin treatment, and coronary events.
    Campos H; Moye LA; Glasser SP; Stampfer MJ; Sacks FM
    JAMA; 2001 Sep; 286(12):1468-74. PubMed ID: 11572739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents.
    Kim BK; Kim DW; Oh S; Yoon SJ; Park S; Jeon DW; Yang JY
    Coron Artery Dis; 2010 May; 21(3):182-8. PubMed ID: 20168221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
    Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
    Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
    Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
    Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving lipid evaluation and management in medicare patients hospitalized for acute myocardial infarction.
    Malach M; Quinley J; Imperato PJ; Wallen M
    Arch Intern Med; 2001 Mar; 161(6):839-44. PubMed ID: 11268226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiographic trials of lipid-lowering therapy: an update.
    Mancini GB
    Curr Opin Lipidol; 1995 Dec; 6(6):379-85. PubMed ID: 8750252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases.
    Nakajima K; Nakajima Y; Takeichi S; Fujita MQ
    Atherosclerosis; 2008 May; 198(1):237-46. PubMed ID: 17977545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].
    Baller D; Gleichmann U; Notohamiprodjo G; Weise R; Holzinger J; Montanus H; Betker S; Lehmann J
    Z Kardiol; 1998; 87 Suppl 2():136-44. PubMed ID: 9827472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
    Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
    JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.